<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8"><meta name="generator" content="ABBYY FineReader 15">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:6pt Arial, sans-serif; }
 .font1 { font:7pt Arial, sans-serif; }
 .font2 { font:8pt Arial, sans-serif; }
 .font3 { font:9pt Arial, sans-serif; }
 .font4 { font:10pt Arial, sans-serif; }
 .font5 { font:11pt Arial, sans-serif; }
 .font6 { font:22pt Book Antiqua, serif; }
 .font7 { font:10pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5" style="font-weight:bold;">Open access</span></p>
<p><span class="font5" style="font-weight:bold;">Original research</span></p><div style="border-bottom:solid;"><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font6" style="font-weight:bold;">BMJ Open Smartphone-delivered self-management for first-episode psychosis: the ARIES&nbsp;feasibility randomised controlled trial</span></h1></div><br clear="all"><div>
<p><span class="font5">Thomas Steare</span><a href="http://orcid.org/0000-0002-3881-2018"><span class="font5"> &nbsp;&nbsp;</span></a><span class="font5">,<sup>1</sup> Puffin O’Hanlon,<sup>1</sup> Michelle Eskinazi,<sup>1</sup> David Osborn,<sup>1,2</sup></span></p>
<p><span class="font5">Brynmor Lloyd-Evans,<sup>1,2</sup> Rebecca Jones,<sup>1</sup> Helen Rostill,<sup>3,4</sup> Sarah Amani,<sup>5 </sup>Sonia Johnson</span><a href="http://orcid.org/0000-0002-2219-1384"><span class="font5"> </span></a><span class="font5"><sup>1,2</sup></span></p></div><br clear="all"><div>
<p><span class="font1" style="font-weight:bold;">To cite: </span><span class="font1">Steare T, O'Hanlon P, Eskinazi M, </span><span class="font1" style="font-style:italic;">etal</span><span class="font2" style="font-style:italic;">.</span><span class="font1"> Smartphone-delivered self-management&nbsp;for first-episode psychosis: the&nbsp;ARIES feasibility randomised&nbsp;controlled trial. </span><span class="font1" style="font-style:italic;">BMJ Open&nbsp;</span><span class="font1">2020;</span><span class="font1" style="font-weight:bold;">10</span><span class="font1">:e034927. doi:10.1136/&nbsp;bmjopen-2019-034927</span></p>
<p><span class="font1">► Prepublication history and additional material for this&nbsp;paper are available online. To&nbsp;view these files, please visit&nbsp;the journal online (</span><a href="http://dx.doi"><span class="font1">http://dx.doi</span></a><span class="font1">.&nbsp;org/10.1136/bmjopen-2019-034927).</span></p></div><br clear="all"><div>
<p><span class="font1">Received 11 October 2019 Revised 27 June 2020&nbsp;Accepted 02 July 2020</span></p></div><br clear="all"><div style="border:solid;">
<p><span class="font2" style="font-weight:bold;">Check for updates</span></p></div><br clear="all"><div>
<p><span class="font1">© Author(s) (or their employer(s)) 2020. Re-use&nbsp;permitted under CC BY.&nbsp;Published by BMJ.&nbsp;<sup>1</sup>Division of Psychiatry,&nbsp;University College London,&nbsp;London, UK&nbsp;<sup>2</sup>R&amp;D Department, Camden and&nbsp;Islington NHS Foundation Trust,&nbsp;London, UK&nbsp;<sup>3</sup>University of Surrey, Guildford,&nbsp;UK</span></p>
<p><span class="font1"><sup>4</sup>Surrey and Borders Partnership NHS Foundation Trust,&nbsp;Leatherhead, UK&nbsp;</span><span class="font0">5</span><span class="font1">Early Intervention in Psychosis&nbsp;Programme (South of England),&nbsp;Oxford, UK</span></p></div><br clear="all">
<h2><a name="bookmark1"></a><span class="font2" style="font-weight:bold;">ABSTRACT</span></h2>
<p><span class="font1" style="font-weight:bold;">Objectives </span><span class="font1">To test the feasibility and acceptability of a randomised controlled trial (RCT) to evaluate a&nbsp;Smartphone-based self-management tool in Early&nbsp;Intervention in Psychosis (EIP) services.</span></p>
<p><span class="font1" style="font-weight:bold;">Design </span><span class="font1">A two-arm unblinded feasibility RCT. </span><span class="font1" style="font-weight:bold;">Setting </span><span class="font1">Six NHS EIP services in England.</span></p>
<p><span class="font1" style="font-weight:bold;">Participants </span><span class="font1">Adults using EIP services who own an Android Smartphone. Participants were recruited until the&nbsp;recruitment target was met (n=40).</span></p>
<p><span class="font1" style="font-weight:bold;">Interventions </span><span class="font1">Participants were randomised with a 1:1 allocation to one of two conditions: (1) treatment as&nbsp;usual from EIP services (TAU) or (2) TAU plus access to&nbsp;My Journey 3 on their own Smartphone. My Journey&nbsp;3 features a range of self-management components&nbsp;including access to digital recovery and relapse prevention&nbsp;plans, medication tracking and symptom monitoring.&nbsp;My Journey 3 use was at the users' discretion and was&nbsp;supported by EIP service clinicians. Participants had&nbsp;access for a median of 38.1 weeks.</span></p>
<p><span class="font1" style="font-weight:bold;">Primary and secondary outcome measures </span><span class="font1">Feasibility outcomes included recruitment, follow-up rates and&nbsp;intervention engagement. Participant data on mental&nbsp;health outcomes were collected from clinical records and&nbsp;from research assessments at baseline, 4 months and 12&nbsp;months.</span></p>
<p><span class="font1" style="font-weight:bold;">Results </span><span class="font1">83% and 75% of participants were retained in the trial at the 4-month and 12-month assessments. All&nbsp;treatment group participants had access to My Journey&nbsp;3 during the trial, but technical difficulties caused delays&nbsp;in ensuring timely access to the intervention. The median&nbsp;number of My Journey 3 uses was 16.5 (IQR 8.5 to 23)&nbsp;and median total minutes spent using My Journey 3 was&nbsp;26.8 (IQR 18.3 to 57.3). No serious adverse events were&nbsp;reported.</span></p>
<p><span class="font1" style="font-weight:bold;">Conclusions </span><span class="font1">Recruitment and retention were feasible. Within a trial context, My Journey 3 could be successfully&nbsp;delivered to adults using EIP services, but with relatively&nbsp;low usage rates. Further evaluation of the intervention in a&nbsp;larger trial may be warranted, but should include attention&nbsp;to implementation.</span></p>
<p><span class="font1" style="font-weight:bold;">Trial registration </span><span class="font1">ISRCTN10004994.</span></p><div>
<p><span class="font1" style="font-weight:bold;">Correspondence to</span></p>
<p><span class="font1">Prof Sonia Johnson;</span></p>
<p><a href="mailto:s.johnson@ucl.ac.uk"><span class="font1">s.johnson@ucl.ac.uk</span></a></p></div><br clear="all">
<h2><a name="bookmark2"></a><span class="font2" style="font-weight:bold;">INTRODUCTION</span></h2>
<p><span class="font7">Early Intervention in Psychosis (EIP) services have been established across the UK to</span></p>
<p><span class="font2" style="font-weight:bold;">Strengths and limitations of this study</span></p>
<ul style="list-style:none;"><li>
<p><a name="bookmark3"></a><span class="font2">► </span><span class="font1">Participant data were collected from a wide range&nbsp;of sources including questionnaires, patient records&nbsp;and from the app.</span></p></li><li>
<p><a name="bookmark4"></a><span class="font2">► </span><span class="font1">Participants were followed up for a 12-month period; longer than the majority of feasibility trials investigating Smartphone apps for psychosis.</span></p></li><li>
<p><a name="bookmark5"></a><span class="font2">► </span><span class="font1">We were not able to blind researchers or participants to their treatment allocation.</span></p></li><li>
<p><a name="bookmark6"></a><span class="font2">► </span><span class="font1">The study recruited users of Early Intervention in&nbsp;Psychosis services that own an Android Smartphone,&nbsp;limiting sample representativeness.</span></p></li><li>
<p><a name="bookmark7"></a><span class="font2">► </span><span class="font1">This is a feasibility study and therefore does not&nbsp;have the statistical power to conclude the effectiveness of the intervention.</span></p></li></ul>
<p><span class="font7">provide care to adults during the 3 years following an initial episode of psychosis.&nbsp;There is evidence that such services are effective and cost-effective,</span><a href="#bookmark8"><span class="font7"><sup>1 2</sup></span></a><span class="font7"> resulting in improvement in a range of outcomes, yet challenges&nbsp;remain. Relapse rates for EIP service users&nbsp;are high</span><a href="#bookmark9"><span class="font7"><sup>3</sup></span></a><span class="font7"> particularly after discharge</span><a href="#bookmark10"><span class="font7"><sup>4 5</sup> </span></a><span class="font7">and&nbsp;limited adherence with antipsychotic medication is common.</span><a href="#bookmark11"><span class="font7"><sup>6</sup></span></a><span class="font7"> There are also difficulties accessing psychosocial interventions,</span><a href="#bookmark12"><span class="font7"><sup>7</sup></span></a><span class="font7"><sup>&nbsp;</sup>including supported self-management.</span></p>
<p><span class="font7">Illness self-management is an approach designed to support people to manage longterm health conditions by developing their&nbsp;ability to recognise and monitor symptoms&nbsp;and early warning signs of relapse, identify&nbsp;and avoid stressors, make plans for achieving&nbsp;their own recovery and effectively use coping&nbsp;strategies.</span><a href="#bookmark13"><span class="font7"><sup>8</sup> </span></a><span class="font7">For people with psychosis, selfmanagement tools have been shown to&nbsp;reduce psychological distress, improve medication adherence and reduce the likelihood&nbsp;of future hospital admissions.</span><a href="#bookmark14"><span class="font7"><sup>9-11</sup> </span></a><span class="font7">In a recent&nbsp;meta-analysis, self-management interventions&nbsp;for severe mental illness were also found to&nbsp;have a significant benefit on patient-valued</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all">
<p><span class="font7">outcomes of personal recovery, hope and self-efficacy.</span><a href="#bookmark15"><span class="font7"><sup>12</sup></span></a><span class="font7"><sup> </sup>Despite clinician-supported self-management&nbsp;programmes being mandated in current UK treatment&nbsp;guidelines for first-episode psychosis,</span><a href="#bookmark16"><span class="font7"><sup>13</sup></span></a><span class="font7"> there is a lack&nbsp;of well-evaluated tools to support delivery within EIP&nbsp;services. There is a clear need to overcome implementation barriers affecting the delivery of self-management&nbsp;to those likely to benefit from it.</span><a href="#bookmark15"><span class="font7"><sup>12</sup></span></a><span class="font7"> A potentially convenient and economical way of achieving this is via the use&nbsp;of digital technology such as Smartphones.</span><a href="#bookmark17"><span class="font7"><sup>14</sup></span></a></p>
<p><span class="font7">Smartphones can run advanced software known as apps that hold promise as an effective tool to assist the&nbsp;monitoring and treatment of mental health problems.&nbsp;Smartphone ownership is rapidly growing worldwide</span><a href="#bookmark18"><span class="font7"><sup>15</sup></span></a><span class="font7"><sup>&nbsp;</sup>with a significant number of developed countries with&nbsp;ownership rates of more than 80%.</span><a href="#bookmark19"><span class="font7"><sup>16</sup></span></a><span class="font7"> Adults with severe&nbsp;mental health problems have comparable Smartphone&nbsp;ownership rates with the general population,</span><a href="#bookmark20"><span class="font7"><sup>17-19</sup></span></a><span class="font7"> and&nbsp;there is a growing consensus that adults with psychosis&nbsp;are open to using Smartphones to access mental health&nbsp;interventions.</span><a href="#bookmark21"><span class="font7"><sup>20 21</sup> </span></a><span class="font7">Smartphones also provide high accessibility to the internet and are commonly carried on the&nbsp;person, meaning apps can be easily accessed at times&nbsp;and locations convenient for the user. Accordingly,&nbsp;Smartphones have the capacity to deliver time-unlimited&nbsp;mental health interventions, such as self-management&nbsp;tools, and ultimately the potential to increase access to&nbsp;effective care and reduce healthcare costs.</span><a href="#bookmark22"><span class="font7"><sup>22</sup></span></a><span class="font7"> The benefits&nbsp;of Smartphone apps may also extend beyond the original&nbsp;treatment period with a community team and could be a&nbsp;valuable tool following discharge where the risk of relapse&nbsp;is increased.</span><a href="#bookmark10"><span class="font7"><sup>4 5</sup></span></a></p>
<p><span class="font7">The majority of digital health interventions that have been developed for psychosis have been based on existing&nbsp;psychological therapies such as cognitive-behavioural&nbsp;therapy,</span><a href="#bookmark23"><span class="font7"><sup>23 24</sup></span></a><span class="font7"> or other evidence-based interventions,</span><a href="#bookmark24"><span class="font7"><sup>25 26</sup></span></a><span class="font7"><sup>&nbsp;</sup>yet very little is known regarding their effectiveness when&nbsp;delivered in EIP services. A growing number of selfmanagement apps for psychosis have been tested for&nbsp;feasibility and acceptability, including those delivered&nbsp;independently of a clinical setting and those embedded&nbsp;within clinical care.</span><a href="#bookmark25"><span class="font7"><sup>27-29</sup></span></a><span class="font7"> These have shown promising&nbsp;levels of adoption and use in research contexts, yet little&nbsp;is known about their clinical efficacy.</span></p>
<p><span class="font7">To date, only one trial of a self-management app delivered in EIP services has published results regarding the intervention's impact on clinical outcomes.</span><a href="#bookmark26"><span class="font7"><sup>30</sup></span></a><span class="font7"> In the proof-of-concept trial, an active self-management app ‘Actis-sist’ was found to confer benefits over a passive control&nbsp;app. The study suggests that participants who received&nbsp;Actissist had better outcomes regarding their mood&nbsp;and general and negative symptoms post-treatment in&nbsp;comparison with control participants. Actissist features a&nbsp;range of components including self-assessment questions&nbsp;focused on cognitive appraisals, emotions, behaviours&nbsp;and belief convictions and suggests appropriate coping&nbsp;strategies, but does not feature some major cornerstones&nbsp;of self-management such as relapse and recovery plans.&nbsp;Regardless, results from this study suggest that such digital&nbsp;self-management interventions could potentially improve&nbsp;outcomes of people using EIP services. Further trials are&nbsp;needed before firm conclusions can be made regarding&nbsp;the feasibility of conducting randomised controlled trials&nbsp;(RCTs) in this field and of the therapeutic benefits of selfmanagement apps for first-episode psychosis delivered in&nbsp;clinical settings.</span></p>
<p><span class="font7">We aimed to address this evidence gap by conducting a feasibility RCT of a supported self-management Smartphone app, ‘My Journey 3’, designed to help EIP service&nbsp;users recognise early warning signs of illness, recognise and monitor symptoms, and create plans for their&nbsp;recovery. My Journey 3 has been designed to be initially&nbsp;set up in EIP services and used with clinician support, but&nbsp;to also be suitable for independent use. The results of&nbsp;the feasibility RCT are a potential step towards a full-scale&nbsp;trial to assess the effectiveness of the intervention.</span></p>
<p><span class="font7">The objectives of this study were as follows:</span></p>
<ul style="list-style:none;"><li>
<p><a name="bookmark27"></a><span class="font7">1. To determine the acceptability of the My Journey 3&nbsp;self-management app for use in an EIP service context.</span></p></li><li>
<p><a name="bookmark28"></a><span class="font7">2. To determine the feasibility of trial procedures for a&nbsp;definitive trial, including recruitment, intervention enrolment and trial attrition.</span></p></li><li>
<p><a name="bookmark29"></a><span class="font7">3. To test procedures for evaluating intervention engagement and participant outcomes.</span></p></li></ul>
<h2><a name="bookmark30"></a><span class="font2" style="font-weight:bold;">METHODS</span></h2>
<h3><a name="bookmark31"></a><span class="font2" style="font-weight:bold;">Design</span></h3>
<p><span class="font7">The App to support Recovery In Early intervention Services (ARIES) study was an unblinded feasibility RCT&nbsp;with a nested qualitative study comparing a supported&nbsp;self-management Smartphone app (My Journey 3) in&nbsp;addition to treatment as usual (TAU), with a control&nbsp;group receiving TAU only. Participants were randomly&nbsp;allocated to one of the two trial arms in a 1:1 ratio. Since&nbsp;this was a feasibility trial, it was not designed to have sufficient statistical power to assess the effectiveness of the My&nbsp;Journey 3 intervention.</span></p>
<p><span class="font7">As the study was a feasibility trial, prospective registration was not required.</span><a href="#bookmark32"><span class="font7"><sup>31</sup> </span></a><span class="font7">Further details of the methodology are available in the protocol paper.</span><a href="#bookmark33"><span class="font7"><sup>32</sup></span></a><span class="font7"> We have followed the Consolidated Standards of Reporting Trials&nbsp;(CONSORT) statement extension for pilot and feasibility randomised trials for reporting.</span><a href="#bookmark34"><span class="font7"><sup>33</sup> </span></a><span class="font7">A copy of the&nbsp;CONSORT checklist is provided as</span><a href="https://dx.doi.org/10.1136/bmjopen-2019-034927"><span class="font7"> online additional file</span></a><span class="font7">&nbsp;</span><a href="https://dx.doi.org/10.1136/bmjopen-2019-034927"><span class="font7">1</span></a><span class="font7">.</span></p>
<h3><a name="bookmark35"></a><span class="font2" style="font-weight:bold;">Setting</span></h3>
<p><span class="font7">The trial was conducted in six EIP services across three NHS Foundation Trusts in England. EIP services are&nbsp;multidisciplinary community mental health services that&nbsp;provide care coordination to people in the first 3 years&nbsp;of a first-episode psychosis, focusing on engagement,&nbsp;achieving social and clinical recovery and delivering a&nbsp;full range of pharmacological, psychological and social&nbsp;interventions.</span><a href="#bookmark36"><span class="font7"><sup>34</sup></span></a><span class="font7"> The six EIP services as mandated in&nbsp;England provide care for people up to the age of 65, with&nbsp;the potential for adults above the age range to access EIP&nbsp;services if clinically appropriate although these cases are&nbsp;rare. Two of the participating Trusts are located in inner&nbsp;London. The third Trust is located in a county outside&nbsp;of London with both urban and rural areas. Assessments&nbsp;were conducted face-to-face at EIP services, at participants’ homes or at University College London.</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all">
<h3><a name="bookmark37"></a><span class="font2" style="font-weight:bold;">Participants</span></h3>
<p><span class="font7">Participants were recruited from the participating EIP services over 7months. We assumed a conservative 40%&nbsp;attrition rate and accordingly set the target sample size as&nbsp;40 participants to ensure the trial retained 12 completer&nbsp;participants per group (as recommended to assess trial&nbsp;feasibility).</span><a href="#bookmark38"><span class="font7"><sup>35</sup> </span></a><span class="font7">Participants were eligible if they were&nbsp;aged </span><span class="font4">&gt;</span><span class="font7">16 years, had experienced at least one episode&nbsp;of psychosis, were currently on the caseload of an EIP&nbsp;service and owned a Smartphone with an Android operating system. People were excluded from the trial if they&nbsp;lacked capacity to consent to participation, were unable&nbsp;to communicate and understand English, or were considered by their EIP service to pose a high risk to researchers&nbsp;during meetings, even on NHS premises. Familiarity and&nbsp;competence in using digital technology or Smartphones&nbsp;was not an eligibility criterion.</span></p>
<h3><a name="bookmark39"></a><span class="font2" style="font-weight:bold;">Recruitment strategy</span></h3>
<p><span class="font7">Clinicians at the participating EIP services were briefed by the research team and were asked to make initial contact&nbsp;with eligible EIP service users. Clinicians explained the&nbsp;trial to service users and enquired whether the service&nbsp;user would be willing to speak to a researcher about&nbsp;participating in the trial. The researcher then made&nbsp;contact with eligible and potentially willing service users&nbsp;and arranged a face-to-face meeting where the trial was&nbsp;explained further. The researcher provided the trial&nbsp;information sheet (</span><a href="https://dx.doi.org/10.1136/bmjopen-2019-034927"><span class="font7">online additional file 2</span></a><span class="font7">) and assessed&nbsp;the participant’s capacity to provide informed consent.&nbsp;Service users had at least 24 hours after receiving the&nbsp;information sheet to consider their participation. Participants then gave written informed consent to take part,&nbsp;prior to completing the baseline assessment. No participants were recruited via online methods.</span></p>
<h3><a name="bookmark40"></a><span class="font2" style="font-weight:bold;">Randomisation</span></h3>
<p><span class="font7">Following the baseline assessment, participants were randomly allocated in a 1:1 ratio to either the intervention (n=20) or the control group (n=20) by an independent statistician. The treatment group had access to My&nbsp;Journey 3 in addition to TAU, while the control group&nbsp;received TAU only. An independent researcher held the&nbsp;allocation list and did not disclose participants’ allocation&nbsp;to the trial researcher until after completion of the baseline assessments.</span></p>
<p><span class="font7">Due to the nature of the intervention, participants were not blinded to their group allocation. During the recruitment process, participants would have been aware that&nbsp;My Journey 3 was the intervention of interest. As a single&nbsp;researcher carried out the majority of data collection,&nbsp;it was not practical for the allocation of participants to&nbsp;be concealed from the research team. Participants were&nbsp;informed of their allocation by the researcher via a telephone call.</span></p>
<h3><a name="bookmark41"></a><span class="font2" style="font-weight:bold;">Interventions</span></h3>
<h4><a name="bookmark42"></a><span class="font2">My Journey 3</span></h4>
<p><span class="font7">My Journey 3 is a Smartphone app developed for adults accessing EIP services. The aim of the intervention is to&nbsp;develop users’ self-management skills to help them to&nbsp;achieve self-determined recovery goals and avoid future&nbsp;relapses. My Journey 3 is suitable for independent use,&nbsp;but also designed to be used with support from EIP service&nbsp;clinicians who will be able to assist with the completion of&nbsp;the self-management components and initial set-up. It is&nbsp;the developers’ aspiration for My Journey 3 to be used&nbsp;initially in collaboration with EIP service clinicians, and&nbsp;for it to support continuing self-management after users&nbsp;have been discharged from EIP services.</span></p>
<p><span class="font7">The development of My Journey 3 has been through several iterations. The first version (My Journey 1) was&nbsp;created by Surrey and Borders Partnership NHS Foundation Trust with leadership from Sarah Amani, for EIP&nbsp;service users to track their symptoms, set reminders for&nbsp;appointments and share their progress with EIP service&nbsp;clinicians. In developing the current version of My&nbsp;Journey 3, we have drawn on existing paper-and-pen&nbsp;self-management intervention components</span><a href="#bookmark43"><span class="font7"><sup>36 37</sup></span></a><span class="font7"> to allow&nbsp;users to track recovery goals and personalise relapse&nbsp;prevention plans—important cornerstones of illness selfmanagement. The design and the content of My Journey&nbsp;3 was led by a collaboration of researchers, digital health&nbsp;experts, EIP service clinicians and service users. A private&nbsp;app development company based in the UK (MyOxygen;&nbsp;</span><a href="https://myoxygen.uk"><span class="font7">https://myoxygen.uk</span></a><span class="font7">) led the technical development of&nbsp;My Journey 3. To limit costs, My Journey 3 is only compatible with Smartphones with Android operating systems at&nbsp;this stage of testing.</span></p>
<p><span class="font7">My Journey 3 features four key elements of selfmanagement, an approach with demonstrated efficacy in improving social and clinical outcomes for people&nbsp;with psychosis.</span><a href="#bookmark15"><span class="font7"><sup>12</sup> </span></a><span class="font7">Screenshots of the key components are&nbsp;displayed in </span><a href="#bookmark44"><span class="font7">figure 1</span></a><span class="font7">. Users can create a relapse prevention plan, where there is the opportunity to identify and&nbsp;list triggers, early warning signs of relapse and personalised coping strategies to refer to as required and to&nbsp;create a plan to follow if experiencing a crisis. Via the&nbsp;‘My Recovery Plan’ section, users are able to set recovery&nbsp;goals, list actions they can do to encourage well-being and&nbsp;set reminders on their Smartphone to encourage engagement in these activities. Users can also use a tracker to&nbsp;monitor and rate their symptoms and early warning signs&nbsp;over time. In the Symptom Tracker, users are presented&nbsp;with 17 different symptoms and behaviours and are asked&nbsp;to respond via a “Yes/No” format as to whether they have&nbsp;recently experienced these. Users who respond with a</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div><img src="steare2020_files/steare2020-1.jpg" alt="" style="width:248pt;height:274pt;">
<p><a name="bookmark44"></a><span class="font3" style="font-weight:bold;">Figure 1 </span><span class="font3">Screenshots of the My Journey 3 app. (A) The homescreen, (B) the ‘My goals' section of the recovery&nbsp;plan, (C) the ‘Coping with early warning signs' section of&nbsp;the relapse prevention plan, (D) an example item from the&nbsp;Symptom Tracker, (E) the Information section.</span></p></div><br clear="all">
<p><span class="font7">“Yes” are then presented with a 10-point scale (4-point scale for the early warning sign tracker) to rate the severity or&nbsp;frequency of the associated symptoms, with advice on how&nbsp;to manage these symptoms displayed. Psychoeducation&nbsp;on mental health, medication and mental health services&nbsp;is provided in an ‘Information' section. To encourage&nbsp;adherence with medication, users are encouraged to log&nbsp;and track their medication in the ‘Pill Tracker' section.&nbsp;Users are able to set daily alerts to remind them to log&nbsp;whether they have taken their medication. My Journey 3&nbsp;also features weekly discrete notifications to encourage&nbsp;engagement with the app, which can be disabled at the&nbsp;users' preference. The key components of My Journey 3&nbsp;are summarised in </span><a href="#bookmark45"><span class="font7">table 1</span></a><span class="font7">, with further details available in&nbsp;the protocol paper.</span><a href="#bookmark33"><span class="font7"><sup>32</sup></span></a></p>
<p><span class="font7">Prior to the feasibility trial reported in this paper, My Journey 3 was tested by EIP service users in laboratorybased usability tests and in a 1-month field study. The&nbsp;final content of My Journey 3 was then refined based&nbsp;on feedback from individual interviews with the participating EIP service users and clinicians. No changes were&nbsp;made to the content of My Journey 3 during the feasibility RCT. A major technical update to My Journey 3 was&nbsp;carried out in January 2018 to fix compatibility issues with&nbsp;older versions of Android operating systems. This did not&nbsp;require any changes to the trial design.</span></p>
<h5><a name="bookmark46"></a><span class="font2" style="font-style:italic;">Delivery</span></h5>
<p><span class="font7">Following assignment to the treatment group, participants engaged in individual training sessions with a trial researcher and a supporting EIP service clinician.&nbsp;Training sessions were intended to take place within&nbsp;6weeks of the participants' initial baseline assessment,&nbsp;and lasted for approximately 2 hours. During these&nbsp;sessions, the researcher downloaded My Journey 3 onto&nbsp;the participants' Smartphone and gave a demonstration&nbsp;of the app and its main functions. Participants were then&nbsp;encouraged to input appropriate information to specific&nbsp;sections of My Journey 3 with the help of the supporting&nbsp;EIP service clinician in attendance. Following this session,&nbsp;it was hoped that all participants had initial personal&nbsp;recovery plans, relapse prevention plans and crisis plans&nbsp;stored on My Journey 3.</span></p><div>
<table border="1">
<tr><td colspan="3" style="vertical-align:bottom;">
<p><a name="bookmark45"></a><span class="font3" style="font-weight:bold;">Table 1 </span><span class="font3">Key sections of the My Journey 3 Smartphone app</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Section</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Features</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Purpose</span></p></td></tr>
<tr><td>
<p><span class="font3">My recovery plan</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">Things I can do to keep well My goals</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">To encourage users to have regular routines, track activities, set reminders&nbsp;and plan how to achieve long-term goals</span></p></td></tr>
<tr><td>
<p><span class="font3">My relapse prevention plan</span></p></td><td>
<p><span class="font3">Coping with triggers</span></p>
<p><span class="font3">Coping with early warning signs Coping with a crisis</span></p>
<p><span class="font3">Crisis contacts</span></p></td><td>
<p><span class="font3">To help users identify, monitor and cope with triggers and early warning signs&nbsp;To help users create a ‘relapse plan' to&nbsp;follow in times of crisis</span></p></td></tr>
<tr><td>
<p><span class="font3">How are you doing?</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">My mood</span></p>
<p><span class="font3">My early warning signs</span></p>
<p><span class="font3">My tracker</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">For users to monitor symptoms, behaviours and early warning signs and&nbsp;track these experiences over time</span></p></td></tr>
<tr><td>
<p><span class="font3">Pill tracker</span></p></td><td></td><td style="vertical-align:bottom;">
<p><span class="font3">To log whether users have taken their medication each day</span></p></td></tr>
<tr><td>
<p><span class="font3">Information</span></p></td><td>
<p><span class="font3">Medication information Useful websites&nbsp;Emergency services&nbsp;Jargon buster</span></p></td><td>
<p><span class="font3">To provide users with useful information and external links on medication and&nbsp;mental health</span></p>
<p><span class="font3">To identify local emergency services in a time of crisis</span></p>
<p><span class="font3">To provide a glossary of terms that are commonly used in mental health care</span></p></td></tr>
</table></div><br clear="all"><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all">
<p><span class="font7">Participants had access to My Journey 3 on their own Smartphone from the training session until the 12-month&nbsp;time point. Researchers recommended that participants&nbsp;used My Journey 3 at least once a week, but participants&nbsp;had a free choice in how and when they used My Journey&nbsp;3. Participants did not receive any financial incentives to&nbsp;use My Journey 3, and were free to withdraw from using&nbsp;the app or decline the installation of it on to their Smartphone. At the training session, participants were informed&nbsp;by the researcher that My Journey 3 would be not suitable&nbsp;for seeking urgent medical care while in crisis, and that it&nbsp;is not a substitute for human support.</span></p>
<p><span class="font7">To encourage user engagement with My Journey 3 during the trial, supporting EIP service clinicians were&nbsp;asked to provide regular support and encouragement to&nbsp;service users who had access to My Journey 3. Clinicians&nbsp;were asked to discuss recovery goals and relapse prevention plans in routine appointments with participants, and&nbsp;assist with entering these into the appropriate My Journey&nbsp;3 sections. Clinicians had an existing understanding of&nbsp;self-management approaches from their clinical training&nbsp;and practice, and would be able to provide appropriate&nbsp;advice with the intervention components of My Journey&nbsp;3, but they received no formal training on how to implement My Journey 3 into their clinical work. Clinicians’&nbsp;understanding of operating My Journey 3 was from the&nbsp;training sessions only. Clinician support for My Journey&nbsp;3 as part of the trial was not manualised or incentivised.</span></p>
<p><span class="font7">Participants were encouraged to contact the trial researcher in the case of technical problems with My&nbsp;Journey 3. The researcher contacted participants a week&nbsp;after the training session to check that My Journey 3 had&nbsp;been functioning without issues and invited any questions&nbsp;about the app. No further prompts were instigated by the&nbsp;researcher during the trial.</span></p>
<h4><a name="bookmark47"></a><span class="font2">Treatment as usual</span></h4>
<p><span class="font7">All participants received TAU regardless of group allocation. TAU for a person under the care of EIP services typically involves regular meetings with a care coordinator, access to a psychiatrist, psychiatric medication and&nbsp;a range of psychological interventions. EIP services are&nbsp;encouraged to deliver self-management programmes that&nbsp;include advice on symptom management, crisis planning&nbsp;and relapse prevention, generally delivered with paper-and-pen tools if at all.</span><a href="#bookmark36"><span class="font7"><sup>34</sup></span></a><span class="font7"> None of the participating EIP&nbsp;services offered digital interventions or Smartphone apps&nbsp;as part of routine care during the study period, and structured self-management support, including the relapse&nbsp;prevention work recommended in EIP contexts, was&nbsp;inconsistently implemented.</span></p>
<h4><a name="bookmark48"></a><span class="font2">Patient and participant involvement</span></h4>
<p><span class="font7">The development of My Journey 3 has been guided by the input of people with lived experience of psychosis.&nbsp;Initial development of the design and content involved&nbsp;a collaboration between researchers, experts in digital&nbsp;health and service users. Service users provided further&nbsp;input into the design and functionality of MyJourney 3 by&nbsp;providing feedback after taking part in laboratory-based&nbsp;tests and a field study.</span></p>
<h4><a name="bookmark49"></a><span class="font2">Outcomes</span></h4>
<p><span class="font7">Participant data were collected from numerous sources including participant assessments, patient records and&nbsp;anonymous My Journey 3 usage reports. There were no&nbsp;pre-specified criteria for assessing trial feasibility and&nbsp;intervention acceptability.</span></p>
<h5><a name="bookmark50"></a><span class="font2" style="font-style:italic;">Questionnaire measures</span></h5>
<p><span class="font7">Proposed outcome measures for a future trial were assessed at structured face-to-face assessments with&nbsp;a trained researcher at three time points: baseline,&nbsp;4 months post baseline and 12 months post baseline. At&nbsp;all meetings, participants completed self-report questionnaires that have been previously used with people with&nbsp;first-episode psychosis. Participants were given £20 as a&nbsp;thank you for completing the assessment at each time&nbsp;point.</span></p>
<p><span class="font7">At each assessment, we collected sociodemographic data including age, gender, ethnicity, accommodation&nbsp;and living situation, employment status, educational&nbsp;attainment, Smartphone use and use of other mental&nbsp;health apps. The following self-report measures were&nbsp;also collected: social outcomes (Social Outcomes Index&nbsp;(SIX),</span><a href="#bookmark51"><span class="font7"><sup>38</sup></span></a><span class="font7"> score 0-6: higher score=better social outcomes),&nbsp;self-efficacy (Mental Health Confidence Scale (MHCS),</span><a href="#bookmark52"><span class="font7"><sup>39</sup></span></a><span class="font7"><sup>&nbsp;</sup>score 16-96: higher score=greater empowerment), selfrated recovery (Questionnaire about the Process of&nbsp;Recovery (QPR),</span><a href="#bookmark53"><span class="font7"><sup>40</sup></span></a><span class="font7"> intrapersonal score 0-68, interpersonal score 0-20: higher score=greater recovery), mental&nbsp;well-being (Warwick-Edinburgh Mental Well-Being Scale&nbsp;(WEMWBS),</span><a href="#bookmark54"><span class="font7"><sup>41</sup> </span></a><span class="font7">score 14-70: higher score=greater wellbeing) and quality of life and satisfaction with treatment&nbsp;(DIALOG scale,</span><a href="#bookmark55"><span class="font7"><sup>42</sup></span></a><span class="font7"> score 1-7: higher score=greater quality&nbsp;of life/satisfaction with treatment).</span></p>
<p><span class="font7">Clinical structured interviews were also conducted with each participant by the researcher, to assess psychopathology, using the Positive and Negative Syndrome Scale&nbsp;(PANSS).</span><a href="#bookmark56"><span class="font7"><sup>43</sup></span></a><span class="font7"> Higher PANSS scores are indicative of greater&nbsp;severity of each symptom domain.</span></p>
<p><span class="font7">Participants’ engagement with EIP services were measured using the Service Engagement Scale (SES),</span><a href="#bookmark57"><span class="font7"><sup>44</sup></span></a><span class="font7"><sup>&nbsp;</sup>completed by EIP service clinicians known to each participant, typically care co-coordinators. Clinicians completed&nbsp;the SES at baseline and 12 months later, regardless of&nbsp;whether participants attended the 12-month assessment.&nbsp;Higher SES scores are indicative of poorer user engagement with EIP services.</span></p>
<h5><a name="bookmark58"></a><span class="font2" style="font-style:italic;">Patient records</span></h5>
<p><span class="font7">Clinical data were extracted from patient records at baseline and at the 12-month time point. Clinical measures included most recent diagnosis and use of EIP services,&nbsp;other community mental health teams and acute mental&nbsp;health services in the previous 12 months.</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all">
<p><span class="font7">The proposed primary outcome for a future RCT (relapse of psychosis) was operationalised as an admission&nbsp;to an acute mental health service (inpatient psychiatric&nbsp;ward, crisis house, crisis resolution team or acute day care&nbsp;service) during the 12-month trial period as indicated&nbsp;in patient records. This definition of relapse has been&nbsp;used previously in a recent trial of a self-management&nbsp;intervention.</span><a href="#bookmark59"><span class="font7"><sup>45</sup></span></a></p>
<h5><a name="bookmark60"></a><span class="font2" style="font-style:italic;">My Journey 3 use</span></h5>
<p><span class="font7">To assess acceptability of the intervention and user engagement, My Journey 3 usage data were collected for&nbsp;all participants in the treatment group from the training&nbsp;session until the 12-month time point. Whenever users&nbsp;had Wi-Fi internet access on their Smartphone, My&nbsp;Journey 3 automatically uploaded encrypted usage data&nbsp;to a secure server. Data collected included a record of&nbsp;each time the user opened My Journey 3, whether this&nbsp;was in response to a prompt and which components they&nbsp;used. To ensure confidentiality, personal or identifiable&nbsp;data such as text or responses to each sections were not&nbsp;collected.</span></p>
<h5><a name="bookmark61"></a><span class="font2" style="font-style:italic;">Acceptability</span></h5>
<p><span class="font7">Feedback was obtained through semi-structured interviews as part of a nested qualitative study. Individual interviews were conducted at the 4-month time point with both service user participants that received My Journey 3&nbsp;and supporting clinical staff.</span></p>
<h3><a name="bookmark62"></a><span class="font2" style="font-weight:bold;">Analysis</span></h3>
<p><span class="font7">Participant demographic and clinical characteristics, My Journey 3 usage, and rates of participant recruitment and retention were summarised using descriptive&nbsp;statistics. As this was a feasibility RCT, it was not powered&nbsp;to assess the effectiveness of the intervention. Statistical analyses of participant outcome measures were&nbsp;conducted to pilot the methods of analysis for a fully&nbsp;powered effectiveness trial. Logistic regression was used&nbsp;to explore the impact of the My Journey 3 intervention on relapse. Linear regression was used to examine&nbsp;the potential effect of the intervention on continuous&nbsp;outcome measures at 4 months and 12 months separately. We report the effect estimates and corresponding&nbsp;95% CIs only for unadjusted analyses and for analyses&nbsp;adjusting for the baseline measure of the outcome in&nbsp;question. All analyses were performed using STATA V.14&nbsp;after completion of the final participant assessment. No&nbsp;interim analyses were conducted.</span></p>
<p><span class="font7">Qualitative data were coded to themes based on the Acceptability of Healthcare Interventions framework.</span><a href="#bookmark63"><span class="font7"><sup>46</sup></span></a><span class="font7"><sup>&nbsp;</sup>Results of the nested qualitative study exploring the&nbsp;acceptability of My Journey 3 and drivers of engagement&nbsp;and non-adherence will be reported in full elsewhere.&nbsp;Here, we provide a short summary of findings.</span></p>
<h2><a name="bookmark64"></a><span class="font2" style="font-weight:bold;">RESULTS</span></h2>
<h3><a name="bookmark65"></a><span class="font2" style="font-weight:bold;">Feasibility of trial design</span></h3>
<p><span class="font7">Participant flow is detailed in the CONSORT diagram (</span><a href="#bookmark66"><span class="font7">figure 2</span></a><span class="font7">). A total of 40 participants was recruited and&nbsp;randomised (20 to My Journey 3, 20 to TAU) over a&nbsp;7-month period from March 2017 to September 2017.&nbsp;Participants were recruited until the required number of&nbsp;40 was obtained: we do not therefore have a full assessment of the proportion of the teams’ caseload who could&nbsp;have been recruited to a full trial, nor do we know the&nbsp;proportion of approached EIP services users that did not&nbsp;meet eligibility criteria or declined involvement in the&nbsp;trial.</span></p>
<p><span class="font7">Among those recruited to the trial, attrition rates were generally low: 83% (33/40) and 75% (30/40) of participants successfully attended and completed follow-ups&nbsp;at 4 months and 12 months, respectively. At both time&nbsp;points, the follow-up rate was lower in the control group&nbsp;(4months: 65% compared with 100%, 12months: 70%&nbsp;compared with 80%). Patient record data were available&nbsp;for all participants at baseline and for 95% of the sample&nbsp;(38/40) at the 12-month time point. Completion rates of&nbsp;the SES by clinicians were higher at baseline (90%) than&nbsp;at the 12-month time point (67.5%). Follow-up assessments were conducted from July 2017 to October 2018.</span></p>
<p><span class="font7">All participants in the treatment group attended a training session with a researcher and had access to&nbsp;My Journey 3 during the trial. Issues with Smartphone&nbsp;compatibility initially prevented three participants from&nbsp;downloading My Journey 3. Following an update to the&nbsp;system, two of the participants were able to install and&nbsp;access My Journey 3 on their own Smartphones. Two&nbsp;participants were provided with Smartphones with My&nbsp;Journey 3 pre-installed (the app was still incompatible&nbsp;on one participant’s Smartphone despite the update;&nbsp;another participant no longer owned an Android Smartphone after entering the trial). The median length of&nbsp;time from trial enrolment to having access to My Journey&nbsp;3 was 14 weeks (IQR 11 to 17), longer than the planned&nbsp;time of 6 weeks. Participants had access to My Journey 3&nbsp;for a median of 38.1 weeks (IQR 34.8 to 40.7). There were&nbsp;no reported privacy breaches.</span></p>
<p><span class="font7">My Journey 3 usage data were collected for all participants following the training session, with 500 different data entries available for analysis. Within the 500 data&nbsp;entries, 27 (5.4%) were corrupt and were subsequently&nbsp;removed from the analysis. The unusable data can&nbsp;grouped into two types. The first, duplicates of previous&nbsp;data entries that were subsequently removed. The second,&nbsp;entries where the times were implausible (eg, the end&nbsp;time of using My Journey 3 was recorded as occurring&nbsp;before the start time). In addition, a further issue caused&nbsp;errors with accurately recording My Journey 3 usage data&nbsp;of ‘My Recovery Plan’ and ‘My Relapse Plan’ sections. As&nbsp;a result, we were unable to accurately conclude how often&nbsp;participants used these sections.</span></p>
<p><span class="font7">One participant randomised to the control group was wrongly given access to My Journey 3. For the purpose</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div><img src="steare2020_files/steare2020-2.jpg" alt="" style="width:360pt;height:346pt;">
<p><a name="bookmark66"></a><span class="font3" style="font-weight:bold;">Figure 2 </span><span class="font3">CONSORT diagram of the ARIES feasibility trial. Note: DNA, did not attend.</span></p></div><br clear="all">
<p><span class="font7">of the statistical analysis, they are classed as a control participant.</span></p>
<h3><a name="bookmark67"></a><span class="font2" style="font-weight:bold;">Sample characteristics</span></h3>
<p><span class="font7">A summary of demographic and clinical characteristics of the sample is displayed in</span><a href="#bookmark68"><span class="font7"> table 2</span></a><span class="font7">. The sample was&nbsp;predominantly male (n=28, 70%). The mean age of the&nbsp;sample was 29.7 years (SD 9.78) and similar to that of UK&nbsp;cohorts of EIP service users at first presentation.</span><a href="#bookmark69"><span class="font7"><sup>47 48</sup></span></a><span class="font7"> Six&nbsp;participants were over the age of 35, with these participants spread evenly across the two groups. Most participants had a diagnosis of a schizophrenia, schizotypal or&nbsp;delusional disorder (ICD code F20-F29) and were not in&nbsp;paid employment. A quarter of the sample (n=10, 25%)&nbsp;had completed a university degree. Eight (20%) participants had previously used a mental health app.</span></p>
<h3><a name="bookmark70"></a><span class="font2" style="font-weight:bold;">My Journey 3 use</span></h3>
<p><span class="font7">The level of My Journey 3 use was highly skewed. The median number of times My Journey 3 was used per&nbsp;participant during the trial was 16.5 (IQR 8.5 to 23).&nbsp;Participants accessed My Journey 3 on a median of 3.22%&nbsp;(IQR 1.89 to 6.36) of the days it was available to them,&nbsp;equating to My Journey 3 being used on average once&nbsp;every 31 days (IQR 15.7 to 52.9). Participants spent a&nbsp;median of 26.8 min (IQR 18.3 to 57.3) in total using My&nbsp;Journey 3 over the course of the trial. Eight participants&nbsp;(40%) used My Journey 3 for longer than 30 min in total.</span></p>
<p><span class="font7">Five participants (25%) were still using MyJourney 3 six months after downloading it; however, one participant&nbsp;never used the app after the training session (</span><a href="#bookmark71"><span class="font7">figure 3</span></a><span class="font7">).&nbsp;Half of the participants (n=10) stopped using MyJourney&nbsp;3 within the first 3 months after the training session.</span></p>
<p><span class="font7">The average number of uses by participants for each My Journey 3 component is displayed in</span><a href="#bookmark72"><span class="font7"> table 3</span></a><span class="font7">. The&nbsp;most frequently accessed section was the “How are you&nbsp;doing?” Symptom Tracker section (median uses 3; IQR 1&nbsp;to 6); however, data on how frequently users accessed ‘My&nbsp;Recovery Plan’ and ‘My Relapse Plan’ are unavailable.&nbsp;The ‘Information’ section was accessed the fewest times,&nbsp;with 25% (n=5) of participants in the treatment group&nbsp;never using that section following the training session.&nbsp;Just over 7% of MyJourney 3 uses were initiated following&nbsp;a prompt from the app.</span></p>
<h3><a name="bookmark73"></a><span class="font2" style="font-weight:bold;">My Journey 3 acceptability</span></h3>
<p><span class="font7">Qualitative interviews were conducted with all participants who received MyJourney 3 and the majority of clinical staff&nbsp;who supported its delivery. In general, most service user&nbsp;participants found My Journey 3 to be acceptable, and&nbsp;a number of participants reported a clear benefit from&nbsp;using it. Barriers affecting use were identified including</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http:ZZbmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div>
<table border="1">
<tr><td colspan="3" style="vertical-align:bottom;">
<p><a name="bookmark68"></a><span class="font3" style="font-weight:bold;">Table 2 </span><span class="font3">Key demographic and clinical characteristics of the sample at baseline</span></p></td></tr>
<tr><td></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Control (n=20)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">My Journey 3 (n=20)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Age (years)-mean (SD), (min, max</span><span class="font3">)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">30 (10.1), (18.8, 64.7)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">29.4 (9.7), (17.6, 52.4)</span></p></td></tr>
<tr><td colspan="3">
<p><span class="font3" style="font-weight:bold;">Gender</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Female</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">7 (35%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">5 (25%)</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Ethnicity</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">White British</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">6 (30%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">8 (40%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Any other white/Mixed white</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Black African</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">5 (25%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Black Caribbean</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Black Other</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Asian Indian</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Asian Other</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Other/Mixed other</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td></tr>
<tr><td colspan="3">
<p><span class="font3" style="font-weight:bold;">Education</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Undergraduate degree</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">6 (30%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4 (20%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Some University but no degree</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Higher National Degree or professional qualification</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">A Levels or equivalent</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4 (20%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">GCSEs or equivalent</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4 (20%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">6 (30%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">No qualifications</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Missing</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Employment status</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Employed — more than 16 hours a week</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4 (20%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4 (20%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Employed — less than 16 hours a week</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Voluntary work</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">In study or training</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Unemployed or exempt due to disability</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">8 (40%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">8 (40%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Missing</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4 (20%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Primary diagnosis (ICD-10 code)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">F10—F19: Mental and behavioural disorder due to psychoactive substance use</span></p></td><td>
<p><span class="font3">1 (5%)</span></p></td><td>
<p><span class="font3">0</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">F20-F29: Schizophrenia, schizotypal and delusional disorder</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">16 (80%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">13 (65%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">F30-F39: Mood disorder</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">5 (25%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Missing</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (10%)</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Admission to an acute mental health service in previous year</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Yes</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">11 (55%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10 (50%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">SIX—mean (SD), (min, max)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3.2 (1.5), (0, 6)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3.6 (1.5), (1, 6)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">MHCS—mean (SD), (min, max)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">59.7 (17.8), (16, 82)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">61.2 (12.6), (38, 78)</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">QPR—mean (SD), (min, max)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Intrapersonal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">45.7 (12), (22, 68)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">42.2 (10.6), (24, 60)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Interpersonal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">13.7 (2.7), (9, 19)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">12.9 (3.4), (5, 19)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">WEMWBS—mean (SD), (min, max)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">43.4 (11.6), (25, 69)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">40.3 (10.2), (23, 57)</span></p></td></tr>
<tr><td colspan="3" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">DIALOG—mean (SD), (min, max)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Quality of life</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4.5 (1), (2.8, 6.5)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4.4 (0.8), (3, 5.7)</span></p></td></tr>
<tr><td>
<p><span class="font3">Treatment satisfaction</span></p></td><td>
<p><span class="font3">5.4 (0.7), (4.3, 7)</span></p></td><td>
<p><span class="font3">4.8 (0.7), (3.7, 6)</span></p></td></tr>
</table>
<p><span class="font3">Continued</span></p></div><br clear="all"><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div>
<table border="1">
<tr><td colspan="3" style="vertical-align:middle;">
<p><span class="font3" style="font-weight:bold;">Table 2 </span><span class="font3">Continued</span></p></td></tr>
<tr><td></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Control (n=20)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">My Journey 3 (n=20)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">PANSS—mean (SD), (min, max)</span></p></td><td></td><td></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Positive</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10.9 (5), (7, 22)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">11.3 (4.2), (7, 19)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Negative</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10.7 (2.5), (7, 19)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">11.8 (4.5), (7, 20)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">General</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">26.6 (6), (17, 39)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">26.2 (8), (16, 46)</span></p></td></tr>
<tr><td>
<p><span class="font3" style="font-weight:bold;">SES—mean (SD), (min, max)</span></p></td><td>
<p><span class="font3">11.3 (7.9), (0, 26)</span></p></td><td>
<p><span class="font3">9.6 (7), (0, 23)</span></p></td></tr>
<tr><td>
<p><span class="font2">All statistics are reported N (%) unless otherwise specified. group participants, one treatment group participant.</span></p></td><td colspan="2">
<p><span class="font2">Missing data: PANSS scores—one control group participant, SES—three control</span></p></td></tr>
</table></div><br clear="all">
<p><span class="font7">a lack of clinician support and concerns around data privacy. A key theme for staff was that they often did not&nbsp;have the time to provide regular support to participants&nbsp;with My Journey 3.</span></p>
<h3><a name="bookmark74"></a><span class="font2" style="font-weight:bold;">Participant outcomes</span></h3>
<p><span class="font7">No research-related serious adverse events were recorded. Psychotic and general symptoms (measured by the&nbsp;PANSS) were generally low at all times for both groups,&nbsp;suggesting a stable sample. Summary statistics and estimated effect sizes of participant outcomes are displayed&nbsp;in</span><a href="#bookmark75"><span class="font7"> table 4</span></a><span class="font7">. Inspection of the effect sizes and confidence&nbsp;intervals suggest that were no obvious differences for any&nbsp;outcome measure between the treatment and control&nbsp;group at either time point.</span></p>
<p><span class="font7">Of the 38 participants whose patient records data were available, only five experienced a relapse during the trial,&nbsp;as indicated by using an acute mental health service. In the&nbsp;treatment group, 15% of participants (3/20) experienced</span></p><img src="steare2020_files/steare2020-3.jpg" alt="" style="width:248pt;height:207pt;">
<p><a name="bookmark71"></a><span class="font3" style="font-weight:bold;">Figure 3 </span><span class="font3">Bar chart displaying how long after the training session participants disengaged with My Journey 3. For the&nbsp;participants aged over 35, one participant disengaged in the&nbsp;first month (second column), one between 3 and 6 months&nbsp;(fourth column) and the other 35+ participant was still using&nbsp;My Journey 3 six months after the training session (fifth&nbsp;column).</span></p>
<p><span class="font7">a relapse during the trial period compared with 11% (2/18) in the control group. We found no evidence of a&nbsp;difference in relapse between the two groups (OR 1.41;&nbsp;95% CI 0.21 to 9.58), but did not have sufficient power for&nbsp;an informative test.</span></p>
<h2><a name="bookmark76"></a><span class="font2" style="font-weight:bold;">DISCUSSION</span></h2>
<p><span class="font7">The present study examined the feasibility of conducting an RCT of a supported self-management Smartphone app&nbsp;in EIP services. My Journey 3 aims to facilitate recovery&nbsp;and prevent relapse primarily via the digital delivery of&nbsp;previously developed paper-and-pen self-management&nbsp;tools. The trial indicates that recruitment and retention&nbsp;in an RCT evaluating My Journey 3 is feasible, and that&nbsp;MyJourney 3 can be delivered in EIP services. The level of&nbsp;My Journey 3 use was relatively low across the trial period.</span></p>
<p><span class="font7">Building on from extensive preliminary work with NHS staff and service users, adults with lived experience of&nbsp;psychosis and experts in digital health, we were able to&nbsp;successfully develop a self-management Smartphone app&nbsp;that can be used in EIP services. My Journey 3 appeared&nbsp;to be safe with no related serious adverse events reported.&nbsp;My Journey 3 was successfully delivered to all participants&nbsp;in the treatment group; however, technical problems with&nbsp;the intervention caused significant delays in providing&nbsp;access. Prior to any future evaluations, technical problems&nbsp;with My Journey 3 will need to be identified and fixed to&nbsp;ensure the intervention is implemented as intended.</span></p>
<p><span class="font7">My Journey 3 use varied considerably between participants, with only a small proportion of participants frequently engaging with the app after obtaining access&nbsp;to it. This raises questions about whether use was at a&nbsp;level where it is likely that useful self-management activities were taking place: certainly not enough time was&nbsp;spent regularly enough for participants to be engaging&nbsp;in detailed monitoring of symptoms and early warning&nbsp;signs, tracking medication and activities and referring to&nbsp;crisis or recovery plans. Despite that, 40% of participants&nbsp;used My Journey 3 for a minimum of 30 minutes which&nbsp;could be an adequate amount of time for users to effectively monitor relapse signs and follow a crisis plan when&nbsp;needed. We have not found evidence on how regularly EIP&nbsp;service users make use of pen-and-paper self-management</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div>
<table border="1">
<tr><td colspan="4" style="vertical-align:bottom;">
<p><a name="bookmark72"></a><span class="font3" style="font-weight:bold;">Table 3 </span><span class="font3">Participant use of My Journey 3 and various sections</span></p></td></tr>
<tr><td></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Number of times used per participant</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Days used while having access to My Journey 3 (%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Participants that did not use app or section—n (%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">My Journey 3</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">16.5 (8.5 to 23)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3.22 (1.89 to 6.36)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1 (5%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">How are you doing?</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (1 to 6)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1.08 (0.4 to 2.12)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Pill tracker</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2 (1 to 3.5)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.73 (0.36 to 1.07)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3 (15%)</span></p></td></tr>
<tr><td>
<p><span class="font3">Information</span></p></td><td>
<p><span class="font3">1 (0 to 2.5)</span></p></td><td>
<p><span class="font3">0.48 (0.18 to 0.7)</span></p></td><td>
<p><span class="font3">5 (25%)</span></p></td></tr>
<tr><td colspan="4" style="vertical-align:middle;">
<p><span class="font2">All median (IQR), except when stated.</span></p></td></tr>
</table></div><br clear="all">
<p><span class="font7">interventions delivered in routine settings, and this was not measured in our trial. Long-term engagement with&nbsp;My Journey 3 appears a challenge, but low levels of app&nbsp;use is a common phenomenon with market research&nbsp;showing that 62% of users stop using Smartphone apps&nbsp;after 10 or fewer uses.</span><a href="#bookmark77"><span class="font7"><sup>49</sup></span></a></p>
<p><span class="font7">Age has been shown to be an important factor linked to engagement with mental health apps and general Smartphone use,</span><a href="#bookmark78"><span class="font7"><sup>50</sup></span></a><span class="font7"> and could partially explain differences in&nbsp;user engagement of My Journey 3. The treatment group,&nbsp;however, featured only a small number of participants&nbsp;from older age groups. We therefore lack informative&nbsp;data regarding app engagement for older participants&nbsp;and we are accordingly unable to explore if engagement&nbsp;and pattern of use of My Journey 3 varied between age&nbsp;groups.</span></p>
<p><span class="font7">Participant retention for research data collection was high, with 75% of the sample attending the 12-month&nbsp;follow-up assessment, and is comparable with other&nbsp;Smartphone app studies.</span><a href="#bookmark79"><span class="font7"><sup>51</sup> </span></a><span class="font7">Completion rates of the SES&nbsp;by EIP service clinicians were much lower at the 12-month&nbsp;follow-up in comparison with baseline, potentially due&nbsp;to staff changes and participants being discharged from&nbsp;services. Recruitment strategies were largely successful;&nbsp;however, data are lacking on overall proportion of&nbsp;caseload recruited, reasons for non-inclusion and the&nbsp;numbers that were assessed for eligibility, thus limiting&nbsp;the conclusions we can make regarding trial feasibility.</span></p>
<p><span class="font7">The trial was not powered to detect effectiveness, and, as expected with our small number of participants, we&nbsp;found no significant differences between groups on any&nbsp;outcomes, with CIs generally including substantial effects&nbsp;in either direction. Accordingly, we cannot draw any&nbsp;conclusions regarding the potential impact of MyJourney&nbsp;3 as a mental health intervention. The proposed primary&nbsp;outcome for a full-scale trial, relapse as defined by use of&nbsp;an acute mental health service during the trial period, was&nbsp;marked by low event rates. Only five participants (12.5%)&nbsp;experienced a relapse during the 1-year follow-up period,&nbsp;compared with expected levels of 12% to 47%.</span><a href="#bookmark80"><span class="font7"><sup>52</sup></span></a><span class="font7"> Consideration should be given to whether relapse, or our measure&nbsp;of relapse, is an appropriate outcome for a future RCT&nbsp;of this intervention. Symptom severity or alternatively&nbsp;patient-valued outcomes of personal recovery that selfmanagement interventions have been shown to benefit&nbsp;may be more suitable primary outcomes in a future large-scale trial.</span><a href="#bookmark15"><span class="font7"><sup>12</sup></span></a></p>
<h3><a name="bookmark81"></a><span class="font2" style="font-weight:bold;">Strengths and limitations</span></h3>
<p><span class="font7">My Journey 3 has been developed with extensive stakeholder input, and the intervention has been tested through laboratory testing and a field study prior to the&nbsp;feasibility RCT. In comparison with previous studies,</span><a href="#bookmark79"><span class="font7"><sup>51</sup></span></a><span class="font7"><sup>&nbsp;</sup>participants had access to the app for a longer period of&nbsp;time. Participants’ app use and usage data may be more&nbsp;reflective of real-world use as a result. Participant data were&nbsp;also collected from a wide range of methods including&nbsp;from participant assessments and patient records. The&nbsp;proposed primary outcome for a future RCT (relapse)&nbsp;was measured objectively and data were obtained for 95%&nbsp;of participants.</span></p>
<p><span class="font7">We recruited until the required number of participants was obtained rather than screening caseloads objectively:&nbsp;as a result, we are not aware of the proportion eligible&nbsp;who were recruited, reasons for non-eligibility and how&nbsp;many EIP service users declined to take part and why.&nbsp;This limits our understanding of how feasible conducting&nbsp;a large-scale trial of this intervention would be. In addition, there were problems with the usage data, which&nbsp;impacts the reliability of our conclusions regarding how&nbsp;often participants engaged with My Journey 3.</span></p>
<p><span class="font7">The trial did not feature an active digital placebo for the control group, meaning that non-specifics of Smartphone use could not be controlled for. Furthermore, data&nbsp;were not collected during the study period from either&nbsp;group regarding frequency of completing recovery work&nbsp;such as relapse prevention plans, recovery plans or crisis&nbsp;plans either in paper-and-pen or digital format, limiting&nbsp;our understanding of whether access to My Journey 3&nbsp;facilitated increased access to self-management activities.</span></p>
<p><span class="font7">Although clinicians were encouraged to support participants with My Journey 3, support was not manualised and clinicians did not have personal access to the app or&nbsp;associated data, potentially limiting the level and quality&nbsp;of the support offered and therefore user engagement.&nbsp;Future developments of My Journey 3 should focus on&nbsp;effective implementation and delivery within healthcare&nbsp;settings, and there should be considerations on how to&nbsp;facilitate secure data-sharing between My Journey 3 and&nbsp;healthcare records or other secure web-based platforms&nbsp;dependent on user consent, which is likely to increase&nbsp;clinician engagement with the app and its utility.</span><a href="#bookmark82"><span class="font7"><sup>53</sup></span></a></p>
<p><span class="font7">We did also not define pre-specified criteria for assessing the feasibility of a RCT and the acceptability of&nbsp;My Journey 3. Instead, we will consider all findings from</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div>
<table border="1">
<tr><td colspan="7" style="vertical-align:bottom;">
<p><a name="bookmark75"></a><span class="font3" style="font-weight:bold;">Table 4 </span><span class="font3">Summary statistics and unadjusted and adjusted treatment effects</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">4-month scores</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Control (n=13)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">My Journey 3 (n=20)</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Unadjusted analysis</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Analysis adjusted for baseline score</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Mean (SD)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Mean (SD)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Estimated difference</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">95% CI</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Estimated difference</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">95% CI</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">SIX </span><span class="font3">(Social Outcomes)</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">3.3 (1.9)</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">3.6 (1.3)</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">0.29</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">-0.84 to 1.43</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">0.16</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">-0.6 to 0.92</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">MHCS</span></p>
<p><span class="font3">(Mental Health Confidence)</span></p></td><td>
<p><span class="font3">66.4 (12.7)</span></p></td><td>
<p><span class="font3">63 (15.8)</span></p></td><td>
<p><span class="font3">-3.43</span></p></td><td>
<p><span class="font3">-14.1 to 7.25</span></p></td><td>
<p><span class="font3">-4.81</span></p></td><td>
<p><span class="font3">-14.88 to 5.25</span></p></td></tr>
<tr><td colspan="7" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">QPR </span><span class="font3">(Recovery)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Intrapersonal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">47.8 (10.6)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">43.2 (12.2)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-4.57</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-13 to 3.87</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-2.01</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-8.43 to 4.49</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Interpersonal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">13.9 (2.4)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">13.2 (2.3)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.72</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-2.39 to 0.95</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.42</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.97 to 1.13</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">MHCS</span></p>
<p><span class="font3">(Mental Health Confidence)</span></p></td><td>
<p><span class="font3">46.1 (9.9)</span></p></td><td>
<p><span class="font3">44 (11.3)</span></p></td><td>
<p><span class="font3">-2.08</span></p></td><td>
<p><span class="font3">-9.9 to 5.74</span></p></td><td>
<p><span class="font3">-0.19</span></p></td><td>
<p><span class="font3">-7.28 to 6.9</span></p></td></tr>
<tr><td colspan="7">
<p><span class="font3" style="font-weight:bold;">DIALOG</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Quality of life</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4.4 (1.2)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4.5 (0.6)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.07</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.58 to 0.71</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.18</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.38 to 0.74</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Treatment satisfaction</span></p></td><td>
<p><span class="font3">5.4 (0.7)</span></p></td><td>
<p><span class="font3">5 (0.5)</span></p></td><td>
<p><span class="font3">-0.38</span></p></td><td>
<p><span class="font3">-0.83 to 0.06</span></p></td><td>
<p><span class="font3">-0.17</span></p></td><td>
<p><span class="font3">-0.6 to 0.25</span></p></td></tr>
<tr><td colspan="7" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">PANSS </span><span class="font3">(Symptom</span></p>
<p><span class="font3">Severity)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Positive</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">9.3 (2.9)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">11.4 (5.1)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2.09</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.24 to 5.4</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1.9</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.49 to 4.3</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Negative</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10 (2.3)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">11.1 (3.9)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1.05</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.51 to 3.62</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.54</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.6 to 2.67</span></p></td></tr>
<tr><td>
<p><span class="font3" style="font-weight:bold;">General</span></p></td><td>
<p><span class="font3">23 (4)</span></p></td><td>
<p><span class="font3">24 (6.7)</span></p></td><td>
<p><span class="font3">1.21</span></p></td><td>
<p><span class="font3">-3.19 to 5.61</span></p></td><td>
<p><span class="font3">1.35</span></p></td><td>
<p><span class="font3">-2.68 to 5.37</span></p></td></tr>
<tr><td></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Control (n=14)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">My Journey 3 (n=16)</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Unadjusted analysis</span></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Analysis adjusted for baseline score</span></p></td></tr>
<tr><td>
<p><span class="font3" style="font-weight:bold;">12-month scores</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Mean (SD)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Mean (SD)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Estimated difference</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">95% CI</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">Estimated difference</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">95% CI</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">SIX </span><span class="font3">(Social Outcomes)</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">3.2 (1.9)</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">3.5 (1.5)</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">0.29</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">-0.97 to 1.54</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">0.29</span></p></td><td style="vertical-align:middle;">
<p><span class="font3">-0.73 to 1.3</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">MHCS</span></p>
<p><span class="font3">(Mental Health Confidence)</span></p></td><td>
<p><span class="font3">66.2 (14.1)</span></p></td><td>
<p><span class="font3">71.1 (12.1)</span></p></td><td>
<p><span class="font3">4.81</span></p></td><td>
<p><span class="font3">-5 to 14.62</span></p></td><td>
<p><span class="font3">3.03</span></p></td><td>
<p><span class="font3">-6.04 to 12.1</span></p></td></tr>
<tr><td colspan="7" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">QPR </span><span class="font3">(Recovery)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Intrapersonal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">47.3 (11.5)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">49.5 (11.1)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">2.2</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-6.25 to 10.7</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">3.21</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-4.12 to 10.5</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Interpersonal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">13.6 (3.4)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">15.1 (3.3)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1.44</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.09 to 3.96</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">1.62</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.89 to 4.12</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">MHCS</span></p>
<p><span class="font3">(Mental Health Confidence)</span></p></td><td>
<p><span class="font3">45.6 (11.3)</span></p></td><td>
<p><span class="font3">49.3 (9.7)</span></p></td><td>
<p><span class="font3">3.61</span></p></td><td>
<p><span class="font3">-4.24 to 11.46</span></p></td><td>
<p><span class="font3">5.03</span></p></td><td>
<p><span class="font3">-1.67 to 11.7</span></p></td></tr>
<tr><td colspan="7">
<p><span class="font3" style="font-weight:bold;">DIALOG</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Quality of life</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">4.7 (0.9)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">5 (0.7)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.28</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.31 to 0.87</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.24</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.33 to 0.81</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Treatment satisfaction</span></p></td><td>
<p><span class="font3">5.3 (1)</span></p></td><td>
<p><span class="font3">5.2 (1.2)</span></p></td><td>
<p><span class="font3">-0.12</span></p></td><td>
<p><span class="font3">-0.93 to 0.69</span></p></td><td>
<p><span class="font3">0.31</span></p></td><td>
<p><span class="font3">-0.42 to 1.04</span></p></td></tr>
<tr><td colspan="7" style="vertical-align:bottom;">
<p><span class="font3" style="font-weight:bold;">PANSS </span><span class="font3">(Symptom</span></p>
<p><span class="font3">Severity)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Positive</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">9.5 (2.1)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10.2 (2.1)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.69</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.98 to 2.36</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.88</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-0.62 to 2.38</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">Negative</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10.2 (2.2)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">10.9 (3.3)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.77</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.51 to 3.05</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">0.14</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.56 to 1.84</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font3">General</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">23.5 (5.4)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">22.1 (3.5)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1.38</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-4.82 to 2.07</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-1</span></p></td><td style="vertical-align:bottom;">
<p><span class="font3">-4.57 to 2.55</span></p></td></tr>
<tr><td>
<p><span class="font3" style="font-weight:bold;">SES </span><span class="font3">(Engagement with Services)</span></p></td><td>
<p><span class="font3">10 (6.2)</span></p></td><td>
<p><span class="font3">9.5 (8)</span></p></td><td>
<p><span class="font3">-0.4</span></p></td><td>
<p><span class="font3">-6.08 to 5.28</span></p></td><td>
<p><span class="font3">3.11</span></p></td><td>
<p><span class="font3">-1.57 to 7.79</span></p></td></tr>
</table>
<p><span class="font3">Continued</span></p></div><br clear="all"><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"><div style="border-bottom:solid;">
<p><span class="font3" style="font-weight:bold;">Table 4 </span><span class="font3">Continued</span></p>
<p><span class="font3" style="font-weight:bold;">Control &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;My Journey 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Analysis adjusted for baseline</span></p>
<p><span class="font3" style="font-weight:bold;">(n=14) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n=16)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unadjusted analysis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;score</span></p>
<p><span class="font3" style="font-weight:bold;">12-month scores &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated</span></p>
<p><span class="font3" style="font-weight:bold;">Mean (SD) Mean (SD) difference 95% CI &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;difference 95% CI</span></p>
<p><span class="font2">Estimated differences and associated 95% Confidence Intervals from linear regression models with thecontrol group as reference. Missing data: 4-month PANSS scores - one control group participant, one treatment group participant. 12-month PANSS scores - two control group&nbsp;participants. Note: 12-month SES data available for 13 control group participants, and 14 treatment group participants.</span></p></div><br clear="all">
<p><span class="font7">the trial, app usage data and feedback from qualitative interviews yet to be reported in determining whether My&nbsp;Journey 3 will be evaluated in a full-scale trial. This allows&nbsp;all data from the RCT to be thoroughly considered, but&nbsp;may be a less objective approach in determining feasibility&nbsp;than using pre-defined criteria. Although the trial was not&nbsp;designed to assess intervention effectiveness, participants&nbsp;and trial researchers were not blinded to group allocation, and as such could have led to an inflation of any&nbsp;observed effects.</span></p>
<p><span class="font7">Finally, the sample consisted of Android Smartphone users who were generally stable and in an appropriate&nbsp;stage of recovery to consider using a self-management&nbsp;Smartphone app. Participants may therefore not be representative of all EIP service users. Furthermore, contact&nbsp;with a researcher within a trial context could have led to&nbsp;increased intervention engagement that would not occur&nbsp;in a real-world clinical environment.</span></p>
<h2><a name="bookmark83"></a><span class="font2" style="font-weight:bold;">CONCLUSIONS</span></h2>
<p><span class="font7">We developed and delivered a self-management Smartphone app for first-episode psychosis in a trial context. Participants were successfully recruited, most engaged at&nbsp;least to some extent with the intervention, and they had&nbsp;high follow-up rates over the 1-year trial period. Based on&nbsp;the data presented, the trial methods appear feasible. My&nbsp;Journey 3 was shown to be safe, but the level of use was&nbsp;lower than anticipated thus potentially limiting its utility.</span></p>
<p><span class="font7">If My Journey 3 is to be further tested in a research setting, attention needs to be given to engagement, a challenge associated with many digital tools in mental health.</span><a href="#bookmark84"><span class="font7"><sup>54</sup></span></a><span class="font7"><sup>&nbsp;</sup>Further usability testing in laboratory and field settings may&nbsp;be a means to improving engagement. Other potential&nbsp;strategies include making more efforts to engage clinicians&nbsp;as well as service users with My Journey 3 by giving them&nbsp;access to the tool and to aspects of the planning and monitoring that service users conduct through it. The app could&nbsp;also potentially be offered as part of a blended approach&nbsp;to self-management, with pen-and-paper tools also used&nbsp;and as a whole service strategy for implementation of selfmanagement. Refinements required before participating to&nbsp;a full trial including participant and assessor blinding and&nbsp;manualised clinician support should be considered prior to&nbsp;conducting a future RCT.</span></p>
<p><span class="font1" style="font-weight:bold;">Twitter </span><span class="font1">Thomas Steare </span><a href="https://twitter.com/tomsteare"><span class="font1">@tomsteare</span></a><span class="font1">, Puffin O'Hanlon </span><a href="https://twitter.com/PuffinOH"><span class="font1">@PuffinOH</span></a><span class="font1">, Michelle Eskinazi </span><a href="https://twitter.com/MichEskinazi"><span class="font1">@MichEskinazi</span></a><span class="font1">, David Osborn </span><a href="https://twitter.com/osborn_ucl"><span class="font1">@osborn_ucl </span></a><span class="font1">and Sonia Johnson </span><a href="https://twitter.com/soniajohnson"><span class="font1">@soniajohnson</span></a></p>
<p><span class="font1" style="font-weight:bold;">Acknowledgements </span><span class="font1">The ARIES research team are grateful to their software collaborators MyOxygen for their technical development and hosting of My&nbsp;Journey 3 and to Ali Mousa for his valuable contribution to the development of&nbsp;the original My Journey app. We are grateful to Max Birchwood for his permission&nbsp;to incorporate ‘Back in the Saddle' into My Journey 3. We are grateful to Rachel&nbsp;Perkins for her permission to adapt the Personal Recovery Plan resource and&nbsp;incorporate in to My Journey 3.</span></p>
<p><span class="font1" style="font-weight:bold;">Contributors </span><span class="font1">SJ is the chief investigator, based at University College London, DO the co-chief investigator and TS the project manager. The trial design&nbsp;was developed by SJ, DO, BL-E and PO. SA, HR, PO and ME have led on the&nbsp;development of the intervention. TS conducted the statistical analysis, with advice&nbsp;from RJ. TS wrote the draft of the paper, which was revised and approved by all&nbsp;authors. All authors approved the final manuscript.</span></p>
<p><span class="font1" style="font-weight:bold;">Funding </span><span class="font1">The research is funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care North&nbsp;Thames at Barts Health NHS Trust (NIHR CLAHRC North Thames). SJ, DO and&nbsp;BL-E are supported by the NIHR Mental Health Research Policy Unit, the NIHR&nbsp;Collaboration for Leadership in Applied Health Research and Care (CLAHRC) North&nbsp;Thames and the UCLH Biomedical Research Centre.</span></p>
<p><span class="font1" style="font-weight:bold;">Disclaimer </span><span class="font1">The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.</span></p>
<p><span class="font1" style="font-weight:bold;">Competing interests </span><span class="font1">None declared.</span></p>
<p><span class="font1" style="font-weight:bold;">Patient consent for publication </span><span class="font1">Not required.</span></p>
<p><span class="font1" style="font-weight:bold;">Ethics approval </span><span class="font1">National Research Ethics Service Committee London—Brent (Research Ethics Committee reference: 15/LO/1453).</span></p>
<p><span class="font1" style="font-weight:bold;">Provenance and peer review </span><span class="font1">Not commissioned; externally peer reviewed.</span></p>
<p><span class="font1" style="font-weight:bold;">Data availability statement </span><span class="font1">No data are available. The datasets generated during and/or analysed during the current study will be available 2 years after the trial end.</span></p>
<p><span class="font1" style="font-weight:bold;">Open access </span><span class="font1">This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits&nbsp;others to copy, redistribute, remix, transform and build upon this work for any&nbsp;purpose, provided the original work is properly cited, a link to the licence is given,&nbsp;and indication of whether changes were made. See:</span><a href="https://creativecommons.org/licenses/by/4.0/"><span class="font1"> https://creativecommons.org/</span></a><span class="font1">&nbsp;</span><a href="https://creativecommons.org/licenses/by/4.0/"><span class="font1">licenses/by/4.0/</span></a><span class="font1">.</span></p>
<p><span class="font1" style="font-weight:bold;">ORCID iDs</span></p>
<p><span class="font1">Thomas Steare</span><a href="http://orcid.org/0000-0002-3881-2018"><span class="font1"> http://orcid.org/0000-0002-3881-2018</span></a><span class="font1"> Sonia Johnson</span><a href="http://orcid.org/0000-0002-2219-1384"><span class="font1"> http://orcid.org/0000-0002-2219-1384</span></a></p>
<h2><a name="bookmark8"></a><span class="font2" style="font-weight:bold;"><a name="bookmark85"></a>REFERENCES</span></h2>
<ul style="list-style:none;"><li>
<p><a name="bookmark86"></a><span class="font1">1 &nbsp;Bird V, Premkumar P, Kendall T, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Early intervention services,&nbsp;cognitive-behavioural therapy and family intervention in early&nbsp;psychosis: systematic review. </span><a href="http://dx.doi.org/10.1192/bjp.bp.109.074526"><span class="font1" style="font-style:italic;">Br J Psychiatry</span></a><span class="font1"> 2010;197:350-6.</span></p></li><li>
<p><a name="bookmark87"></a><span class="font1">2 Tsiachristas A, Thomas T, Leal J, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Economic impact&nbsp;of early intervention in psychosis services: results from a&nbsp;longitudinal retrospective controlled study in England. </span><a href="http://dx.doi.org/10.1136/bmjopen-2016-012611"><span class="font1" style="font-style:italic;">BMJ Open</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2016;6:e012611.</span></p></li><li>
<p><a name="bookmark9"></a><span class="font1"><a name="bookmark88"></a>3 Alvarez-Jimenez M, Parker AG, Hetrick SE, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Preventing&nbsp;the second episode: a systematic review and meta-analysis of&nbsp;psychosocial and pharmacological trials in first-episode psychosis.&nbsp;</span><a href="http://dx.doi.org/10.1093/schbul/sbp129"><span class="font1" style="font-style:italic;">Schizophr Bull</span></a><span class="font1"> 2011;37:619-30.</span></p></li><li>
<p><a name="bookmark10"></a><span class="font1"><a name="bookmark89"></a>4 Kam SM, Singh SP, Upthegrove R. What needs to follow early&nbsp;intervention? Predictors of relapse and functional recovery following&nbsp;first-episode psychosis. </span><a href="http://dx.doi.org/10.1111/eip.12099"><span class="font1" style="font-style:italic;">Early Interv Psychiatry</span></a><span class="font1"> 2015;9:279-83.</span></p></li><li>
<p><a name="bookmark90"></a><span class="font1">5 Puntis S, Oke J, Lennox B. Discharge pathways and relapse&nbsp;following treatment from early intervention in psychosis services.&nbsp;</span><a href="http://dx.doi.org/10.1192/bjo.2018.50"><span class="font1" style="font-style:italic;">BJPsych Open</span></a><span class="font1"> 2018;4:368-74.</span></p><div>
<p><span class="font3">BMJ Open: first published as 10.1136/bmjopen-2019-034927 on 26 August 2020. Downloaded from</span><a href="http://bmjopen.bmj.com/"><span class="font3"> http://bmjopen.bmj.com/ </span></a><span class="font3">on April 3, 2021 by guest. Protected by copyright.</span></p></div><br clear="all"></li></ul>
<p><span class="font1">Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/http://www.ncbi.nlm.nih.gov/pubmed/16822090"><span class="font1" style="font-style:italic;">J Clin</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/http://www.ncbi.nlm.nih.gov/pubmed/16822090"><span class="font1" style="font-style:italic;">Psychiatry</span></a><span class="font1"> 2006;67 Suppl 5:3-8.</span></p>
<p><span class="font1">Haddock G, Eisner E, Boone C, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> An investigation of the implementation of NICE-recommended CBT interventions for people&nbsp;with schizophrenia. </span><a href="http://dx.doi.org/10.3109/09638237.2013.869571"><span class="font1" style="font-style:italic;">J Ment Health</span><span class="font1"> </span></a><span class="font1">2014;23:162-5.</span></p>
<p><span class="font1">Mueser KT, Meyer PS, Penn DL, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> The illness management and recovery program: rationale, development, and preliminary findings.&nbsp;</span><a href="http://dx.doi.org/10.1093/schbul/sbl022"><span class="font1" style="font-style:italic;">Schizophr Bull</span></a><span class="font1"> 2006;32 Suppl 1:S32-43.</span></p>
<p><span class="font1">Mueser KT, Corrigan PW, Hilton DW, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Illness management and recovery: a review of the research. </span><a href="http://dx.doi.org/10.1176/appi.ps.53.10.1272"><span class="font1" style="font-style:italic;">PS</span></a><span class="font1"> 2002;53:1272-84.</span></p>
<p><span class="font1">Cook JA, Copeland ME, Jonikas JA, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Results of a randomized controlled trial of mental illness self-management using wellness&nbsp;recovery action planning. </span><a href="http://dx.doi.org/10.1093/schbul/sbr012"><span class="font1" style="font-style:italic;">Schizophr Bull</span></a><span class="font1"> 2012;38:881-91.</span></p>
<p><span class="font1">Fardig R, Lewander T, Melin L, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> A randomized controlled trial of the illness management and recovery program for persons with&nbsp;schizophrenia. </span><a href="http://dx.doi.org/10.1176/ps.62.6.pss6206_0606"><span class="font1" style="font-style:italic;">Psychiatr Serv</span></a><span class="font1"> 2011;62:606-12.</span></p>
<p><span class="font1">Lean M, Fornells-Ambrojo M, Milton A, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Self-management interventions for people with severe mental illness: systematic review&nbsp;and meta-analysis. </span><a href="http://dx.doi.org/10.1192/bjp.2019.54"><span class="font1" style="font-style:italic;">Br J Psychiatry</span></a><span class="font1"> 2019;214:1-9.</span></p>
<p><span class="font1">NICE Guidance. Psychosis and schizophrenia in adults: prevention and management. Available:</span><a href="https://www.nice.org.uk/guidance/cg178/ifp/chapter/peer-support-and-self-management"><span class="font1"> https://www.nice.org.uk/guidance/</span></a><span class="font1">&nbsp;</span><a href="https://www.nice.org.uk/guidance/cg178/ifp/chapter/peer-support-and-self-management"><span class="font1">cg178/ifp/chapter/peer-support-and-self-management</span></a><span class="font1"> [Accessed 30&nbsp;Jan 2020].</span></p>
<p><span class="font1">Whitehead L, Seaton P. The effectiveness of self-management mobile phone and tablet apps in long-term condition management: a&nbsp;systematic review. </span><a href="http://dx.doi.org/10.2196/jmir.4883"><span class="font1" style="font-style:italic;">J Med Internet Res</span></a><span class="font1"> 2016;18:e97.</span></p>
<p><span class="font1">Poushter J. Smartphone ownership and Internet usage continues to climb in emerging economies. URL, 2016. Available:</span><a href="http://www.pewglobal.org/2016/02/22/smartphone-ownership-and-internet-usage-continues-to-climb-in-emerging-economies/"><span class="font1"> http://www.</span></a><span class="font1">&nbsp;</span><a href="http://www.pewglobal.org/2016/02/22/smartphone-ownership-and-internet-usage-continues-to-climb-in-emerging-economies/"><span class="font1">pewglobal.org/2016/02/22/smartphone-ownership-and-internet-</span></a><span class="font1"></span><a href="http://www.pewglobal.org/2016/02/22/smartphone-ownership-and-internet-usage-continues-to-climb-in-emerging-economies/"><span class="font1">usage-continues-to-climb-in-emerging-economies/</span></a><span class="font1"> [Accessed 30&nbsp;Jan 2019].</span></p>
<p><span class="font1">Wigginton C, Curran M, Broedeur C. </span><span class="font1" style="font-style:italic;">Global mobile consumer trends. </span><span class="font1">2nd edition, 2017. </span><a href="https://www2.deloitte.com/content/dam/Deloitte/us/Documents/technology-media-telecommunications/us-global-mobile-consumer-survey-second-edition.pdf"><span class="font1">https://www2.deloitte.com/content/dam/Deloitte/</span></a><span class="font1">&nbsp;</span><a href="https://www2.deloitte.com/content/dam/Deloitte/us/Documents/technology-media-telecommunications/us-global-mobile-consumer-survey-second-edition.pdf"><span class="font1">us/Documents/technology-media-telecommunications/us-global-</span></a><span class="font1"></span><a href="https://www2.deloitte.com/content/dam/Deloitte/us/Documents/technology-media-telecommunications/us-global-mobile-consumer-survey-second-edition.pdf"><span class="font1">mobile-consumer-survey-second-edition.pdf</span></a></p>
<p><span class="font1">Firth J, Cotter J, Torous J, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Mobile phone ownership and endorsement of “mHealth” among people with psychosis: a&nbsp;meta-analysis of cross-sectional studies. </span><span class="font1" style="font-style:italic;">Schizophrenia Bull&nbsp;</span><span class="font1">2015;42:448-55.</span></p>
<p><span class="font1">Robotham D, Satkunanathan S, Doughty L, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Do we still have a digital divide in mental health? A five-year survey follow-up. </span><a href="http://dx.doi.org/10.2196/jmir.6511"><span class="font1" style="font-style:italic;">J Med</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><a href="http://dx.doi.org/10.2196/jmir.6511"><span class="font1" style="font-style:italic;">Internet Res</span><span class="font1"> </span></a><span class="font1">2016;18:e309.</span></p>
<p><span class="font1">Naslund JA, Aschbrenner KA, Bartels SJ. How people with serious mental illness use smartphones, mobile apps, and social media.&nbsp;</span><a href="http://dx.doi.org/10.1037/prj0000207"><span class="font1" style="font-style:italic;">Psychiatr Rehabil J</span></a><span class="font1"> 2016;39:364-7.</span></p>
<p><span class="font1">Aref-Adib G, O'Hanlon P, Fullarton K, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> A qualitative study of online mental health information seeking behaviour by those with&nbsp;psychosis. </span><a href="http://dx.doi.org/10.1186/s12888-016-0952-0"><span class="font1" style="font-style:italic;">BMC Psychiatry</span></a><span class="font1"> 2016;16:232.</span></p>
<p><span class="font1">Berry N, Lobban F, Bucci S. A qualitative exploration of service user views about using digital health interventions for self-management in&nbsp;severe mental health problems. </span><a href="http://dx.doi.org/10.1186/s12888-018-1979-1"><span class="font1" style="font-style:italic;">BMC Psychiatry</span></a><span class="font1"> 2019;19:35.&nbsp;Proudfoot J. The future is in our hands: the role of mobile phones&nbsp;in the prevention and management of mental disorders. </span><a href="http://dx.doi.org/10.1177/0004867412471441"><span class="font1" style="font-style:italic;">Aust N Z J</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><a href="http://dx.doi.org/10.1177/0004867412471441"><span class="font1" style="font-style:italic;">Psychiatry</span></a><span class="font1"> 2013;47:111-3.</span></p>
<p><span class="font1">Gottlieb JD, Romeo KH, Penn DL, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Web-based cognitive-behavioral therapy for auditory hallucinations in persons with psychosis: a pilot study. </span><a href="http://dx.doi.org/10.1016/j.schres.2013.01.002"><span class="font1" style="font-style:italic;">Schizophr Res</span></a><span class="font1"> 2013;145:82-7.</span></p>
<p><span class="font1">Granholm E, Ben-Zeev D, Link PC, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an&nbsp;interactive text-messaging intervention for medication adherence,&nbsp;socialization, and auditory hallucinations. </span><a href="http://dx.doi.org/10.1093/schbul/sbr155"><span class="font1" style="font-style:italic;">Schizophr Bull</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2012;38:414-25.</span></p>
<p><span class="font1">Ben-Zeev D, Kaiser SM, Brenner CJ, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Development and usability testing of FOCUS: a smartphone system for self-management of&nbsp;schizophrenia. </span><a href="http://dx.doi.org/10.1037/prj0000019"><span class="font1" style="font-style:italic;">Psychiatr Rehabil J</span></a><span class="font1"> 2013;36:289-96.</span></p>
<p><span class="font1">Alvarez-Jimenez M, Bendall S, Lederman R, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> On the HORYZON: moderated online social therapy for long-term recovery in first&nbsp;episode psychosis. </span><a href="http://dx.doi.org/10.1016/j.schres.2012.10.009"><span class="font1" style="font-style:italic;">Schizophr Res</span><span class="font1"> </span></a><span class="font1">2013;143:143-9.</span></p>
<p><span class="font1">Bonet L, Izquierdo C, Escarti MJ, </span><span class="font1" style="font-style:italic;">etal.</span><span class="font1"> Use of mobile technologies in patients with psychosis: a systematic review. </span><a href="http://dx.doi.org/10.1016/j.rpsm.2017.01.003"><span class="font1" style="font-style:italic;">Rev Psiquiatr Salud</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><a href="http://dx.doi.org/10.1016/j.rpsm.2017.01.003"><span class="font1" style="font-style:italic;">Ment</span></a><span class="font1"> 2017;10:168-78.</span></p>
<p><span class="font1">Rus-Calafell M, Schneider S. </span><span class="font1" style="font-style:italic;">Are we there yet?!—a</span><span class="font1"> literature review of recent digital technology advances for the treatment of early&nbsp;psychosis. </span><a href="http://dx.doi.org/10.21037/mhealth.2019.09.14"><span class="font1" style="font-style:italic;">mHealth</span><span class="font1"> </span></a><span class="font1">2020;6:3.</span></p>
<p><span class="font1">Camacho E, Levin L, Torous J. Smartphone apps to support coordinated specialty care for prodromal and early course&nbsp;schizophrenia disorders: systematic review. </span><a href="http://dx.doi.org/10.2196/16393"><span class="font1" style="font-style:italic;">J Med Internet Res</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2019;21:e16393.</span></p>
<ul style="list-style:none;"><li>
<p><a name="bookmark26"></a><span class="font1"><a name="bookmark91"></a>30 Bucci S, Barrowclough C, Ainsworth J, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Actissist: proof-of-concept trial of a theory-driven digital intervention for psychosis.&nbsp;</span><a href="http://dx.doi.org/10.1093/schbul/sby032"><span class="font1" style="font-style:italic;">Schizophr Bull</span></a><span class="font1"> 2018;44:1070-80.</span></p></li><li>
<p><a name="bookmark32"></a><span class="font1"><a name="bookmark92"></a>31 &nbsp;JMIR. Available: </span><a href="https://support.jmir.org/hc/en-us/articles/115001389307-Does-my-trial-RCT-have-to-be-registered-"><span class="font1">https://support.jmir.org/hc/en-us/articles/</span></a><span class="font1">&nbsp;</span><a href="https://support.jmir.org/hc/en-us/articles/115001389307-Does-my-trial-RCT-have-to-be-registered-"><span class="font1">115001389307-Does-my-trial-RCT-have-to-be-registered- </span></a><span class="font1">[Accessed&nbsp;10 Aug 2019].</span></p></li><li>
<p><a name="bookmark33"></a><span class="font1"><a name="bookmark93"></a>32 Steare T, O'Hanlon P, Eskinazi M, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. App to support Recovery in&nbsp;Early Intervention Services (ARIES) study: protocol of a feasibility&nbsp;randomised controlled trial of a self-management Smartphone&nbsp;application for psychosis. </span><a href="http://dx.doi.org/10.1136/bmjopen-2018-025823"><span class="font1" style="font-style:italic;">BMJ Open</span><span class="font1"> </span></a><span class="font1">2019;9:e025823.</span></p></li><li>
<p><a name="bookmark34"></a><span class="font1"><a name="bookmark94"></a>33 Eldridge SM, Chan CL, Campbell MJ, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> CONSORT 2010&nbsp;statement: extension to randomised pilot and feasibility trials. </span><a href="http://dx.doi.org/10.1136/bmj.i5239"><span class="font1" style="font-style:italic;">BMJ</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2016;355:i5239.</span></p></li><li>
<p><a name="bookmark36"></a><span class="font1"><a name="bookmark95"></a>34 National Institute for Health and Care Excellence. </span><span class="font1" style="font-style:italic;">Implementing the&nbsp;early intervention in psychosis access and waiting time standard:&nbsp;guidance.</span><span class="font1"> London: NHS England Publications, 2016: 1-57.</span></p></li><li>
<p><a name="bookmark38"></a><span class="font1"><a name="bookmark96"></a>35 Julious SA. Sample size of 12 per group rule of thumb for a pilot&nbsp;study. </span><a href="http://dx.doi.org/10.1002/pst.185"><span class="font1" style="font-style:italic;">Pharm Stat</span></a><span class="font1"> 2005;4:287-91.</span></p></li><li>
<p><a name="bookmark43"></a><span class="font1"><a name="bookmark97"></a>36 Plaistow J, Birchwood M. Back in the saddle: a guide to relapse&nbsp;prevention. In: Birchwood M, Fowler D, Jackson C, eds. </span><span class="font1" style="font-style:italic;">Eearly&nbsp;intervention in psychosis: a guide to concepts, evidence and&nbsp;interventions.</span><span class="font1"> Chichester: McGraw-Hill, 1996: 239-44.</span></p></li><li>
<p><a name="bookmark98"></a><span class="font1">37 Perkins R, Rinaldi M. </span><span class="font1" style="font-style:italic;">Taking back control: a guide to planning your&nbsp;own recovery.</span><span class="font1"> South West London: St George's Mental Health NHS&nbsp;Trust, 2007.</span></p></li><li>
<p><a name="bookmark51"></a><span class="font1"><a name="bookmark99"></a>38 Priebe S, Watzke S, Hansson L, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Objective social outcomes&nbsp;index (SIX): a method to summarise objective indicators of&nbsp;social outcomes in mental health care. </span><a href="http://dx.doi.org/10.1111/j.1600-0447.2008.01217.x"><span class="font1" style="font-style:italic;">Acta Psychiatr Scand</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2008;118:57-63.</span></p></li><li>
<p><a name="bookmark52"></a><span class="font1"><a name="bookmark100"></a>39 Carpinello SE, Knight EL, Markowitz FE, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. The development of&nbsp;the Mental Health Confidence Scale: a measure of self-efficacy in&nbsp;individuals diagnosed with mental disorders. </span><span class="font1" style="font-style:italic;">Psychiatr Rehabil J&nbsp;</span><span class="font1">2000;23:236-43.</span></p></li><li>
<p><a name="bookmark53"></a><span class="font1"><a name="bookmark101"></a>40 Neil ST, Kilbride M, Pitt L, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. The questionnaire about the process&nbsp;of recovery (QPR): a measurement tool developed in collaboration&nbsp;with service users. </span><a href="http://dx.doi.org/10.1080/17522430902913450"><span class="font1" style="font-style:italic;">Psychosis</span><span class="font1"> </span></a><span class="font1">2009;1:145-55.</span></p></li><li>
<p><a name="bookmark54"></a><span class="font1"><a name="bookmark102"></a>41 Tennant R, Hiller L, Fishwick R, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> The Warwick-Edinburgh mental&nbsp;well-being scale (WEMWBS): development and UK validation. </span><a href="http://dx.doi.org/10.1186/1477-7525-5-63"><span class="font1" style="font-style:italic;">Health</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><a href="http://dx.doi.org/10.1186/1477-7525-5-63"><span class="font1" style="font-style:italic;">Qual Life Outcomes</span><span class="font1"> </span></a><span class="font1">2007;5:63.</span></p></li><li>
<p><a name="bookmark55"></a><span class="font1"><a name="bookmark103"></a>42 Priebe S, McCabe R, Bullenkamp J, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Structured patientclinician communication and 1-year outcome in community mental&nbsp;healthcare. </span><a href="http://dx.doi.org/10.1192/bjp.bp.107.036939"><span class="font1" style="font-style:italic;">Br J Psychiatry</span></a><span class="font1"> 2007;191:420-6.</span></p></li><li>
<p><a name="bookmark56"></a><span class="font1"><a name="bookmark104"></a>43 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome&nbsp;scale (PANSS) for schizophrenia. </span><a href="http://dx.doi.org/10.1093/schbul/13.2.261"><span class="font1" style="font-style:italic;">Schizophr Bull</span></a><span class="font1"> 1987;13:261-76.</span></p></li><li>
<p><a name="bookmark57"></a><span class="font1"><a name="bookmark105"></a>44 Tait L, Birchwood M, Trower P A new scale (SES) to measure&nbsp;engagement with community mental health services. </span><a href="http://dx.doi.org/10.1080/09638230020023570-2"><span class="font1" style="font-style:italic;">J Ment Health</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2002;11:191-8.</span></p></li><li>
<p><a name="bookmark59"></a><span class="font1"><a name="bookmark106"></a>45 Johnson S, Lamb D, Marston L, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Peer-supported selfmanagement for people discharged from a mental health crisis team:&nbsp;a randomised controlled trial. </span><a href="http://dx.doi.org/10.1016/S0140-6736(18)31470-3"><span class="font1" style="font-style:italic;">Lancet</span></a><span class="font1"> 2018;392:409-18.</span></p></li><li>
<p><a name="bookmark63"></a><span class="font1"><a name="bookmark107"></a>46 Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare&nbsp;interventions: an overview of reviews and development of a&nbsp;theoretical framework. </span><a href="http://dx.doi.org/10.1186/s12913-017-2031-8"><span class="font1" style="font-style:italic;">BMC Health Serv Res</span><span class="font1"> </span></a><span class="font1">2017;17:1-13.</span></p></li><li>
<p><a name="bookmark69"></a><span class="font1"><a name="bookmark108"></a>47 Kirkbride JB, Fearon P Morgan C, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Heterogeneity in incidence&nbsp;rates of schizophrenia and other psychotic syndromes: findings from&nbsp;the 3-center AeSOP study. </span><a href="http://dx.doi.org/10.1001/archpsyc.63.3.250"><span class="font1" style="font-style:italic;">Arch Gen Psychiatry</span></a><span class="font1"> 2006;63:250-8.</span></p></li><li>
<p><a name="bookmark109"></a><span class="font1">48 Adamson V, Barrass E, McConville S, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Implementing the access&nbsp;and waiting time standard for early intervention in psychosis in the&nbsp;United Kingdom: an evaluation of referrals and post-assessment&nbsp;outcomes over the first year of operation. </span><a href="http://dx.doi.org/10.1111/eip.12548"><span class="font1" style="font-style:italic;">Early Interv Psychiatry</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2018;12:979-86.</span></p></li><li>
<p><a name="bookmark77"></a><span class="font1"><a name="bookmark110"></a>49 Localytics. 21% of users abandon an app after one use. Available:&nbsp;</span><a href="http://info.localytics.com/blog/21-percent-of-users-abandon-apps-after-one-use"><span class="font1">http://info.localytics.com/blog/21-percent-of-users-abandon-apps-</span></a><span class="font1"></span><a href="http://info.localytics.com/blog/21-percent-of-users-abandon-apps-after-one-use"><span class="font1">after-one-use </span></a><span class="font1">[Accessed 16 May 2019].</span></p></li><li>
<p><a name="bookmark78"></a><span class="font1"><a name="bookmark111"></a>50 Beard C, Silverman AL, Forgeard M, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. Smartphone, social media,&nbsp;and mental health app use in an acute transdiagnostic psychiatric&nbsp;sample. </span><a href="http://dx.doi.org/10.2196/13364"><span class="font1" style="font-style:italic;">JMIR Mhealth Uhealth</span><span class="font1"> </span></a><span class="font1">2019;7:e13364.</span></p></li><li>
<p><a name="bookmark79"></a><span class="font1"><a name="bookmark112"></a>51 Firth J, Torous J. Smartphone apps for schizophrenia: a systematic&nbsp;review. </span><a href="http://dx.doi.org/10.2196/mhealth.4930"><span class="font1" style="font-style:italic;">JMIR Mhealth Uhealth</span><span class="font1"> </span></a><span class="font1">2015;3:e102.</span></p></li><li>
<p><a name="bookmark80"></a><span class="font1"><a name="bookmark113"></a>52 Alvarez-Jimenez M, Priede A, Hetrick SE, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Risk factors for&nbsp;relapse following treatment for first episode psychosis: a systematic&nbsp;review and meta-analysis of longitudinal studies. </span><a href="http://dx.doi.org/10.1016/j.schres.2012.05.007"><span class="font1" style="font-style:italic;">Schizophr Res</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><span class="font1">2012;139:116-28.</span></p></li><li>
<p><a name="bookmark82"></a><span class="font1"><a name="bookmark114"></a>53 Torous J, Woodyatt J, Keshavan M, </span><span class="font1" style="font-style:italic;">et al</span><span class="font1">. A new hope for early&nbsp;psychosis care: the evolving landscape of digital care tools. </span><a href="http://dx.doi.org/10.1192/bjp.2019.8"><span class="font1" style="font-style:italic;">Br J</span></a><span class="font1" style="font-style:italic;">&nbsp;</span><a href="http://dx.doi.org/10.1192/bjp.2019.8"><span class="font1" style="font-style:italic;">Psychiatry</span></a><span class="font1"> 2019;214:269-72.</span></p></li><li>
<p><a name="bookmark84"></a><span class="font1"><a name="bookmark115"></a>54 Aref-Adib G, McCloud T, Ross J, </span><span class="font1" style="font-style:italic;">et al.</span><span class="font1"> Factors affecting&nbsp;implementation of digital health interventions for people with&nbsp;psychosis or bipolar disorder, and their family and friends: a&nbsp;systematic review. </span><a href="http://dx.doi.org/10.1016/S2215-0366(18)30302-X"><span class="font1" style="font-style:italic;">Lancet Psychiatry</span></a><span class="font1"> 2019;6:257-66.</span></p></li></ul>
<p><span class="font1">Steare T, </span><span class="font1" style="font-style:italic;">et al. BMJOpen</span><span class="font1">2020;</span><span class="font1" style="font-weight:bold;">10</span><span class="font1">:e034927. doi:10.1136/bmjopen-2019-034927</span></p>
<p><span class="font2" style="font-weight:bold;">13</span></p>
</body>
</html>